Hans Carl Hasselbalch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9065850/publications.pdf

Version: 2024-02-01

264 papers	10,009 citations	47004 47 h-index	46795 89 g-index
268 all docs	268 docs citations	268 times ranked	6979 citing authors

#	Article	IF	Citations
1	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
2	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
3	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
4	MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 2008, 112, 141-149.	1.4	371
5	Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood, 2012, 119, 3219-3225.	1.4	255
6	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	1.4	229
7	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Haematology,the, 2020, 7, e196-e208.	4.6	199
8	Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leukemia Research, 2013, 37, 214-220.	0.8	198
9	V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 2006, 107, 2098-2100.	1.4	194
10	MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-16.	3.0	155
11	Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood, 2011, 118, 6515-6520.	1.4	149
12	The JAK2 V617F mutation involves Bâ€•and Tâ€lymphocyte lineages in a subgroup of patients with Philadelphiaâ€chromosome negative chronic myeloproliferative disorders. British Journal of Haematology, 2007, 136, 745-751.	2.5	148
13	Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 2013, 121, 1976-1981.	1.4	146
14	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144
15	Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019, 134, 469-479.	1.4	139
16	A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology, 2013, 163, 393-399.	2.5	135
17	B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Gravesâ€™ Disease: A Controlled Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1769-1772.	3.6	133
18	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis â€“ impact on disease phenotype. European Journal of Haematology, 2007, 79, 508-515.	2.2	130

#	Article	IF	Citations
19	The role of cytokines in the initiation and progression of myelofibrosis. Cytokine and Growth Factor Reviews, 2013, 24, 133-145.	7.2	128
20	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 2005, 78, 275-280.	4.1	121
21	Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood, 2008, 112, 3026-3035.	1.4	119
22	Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 2000, 65, 132-139.	2.2	118
23	Increased circulating plateletâ€“leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. European Journal of Haematology, 2001, 66, 143-151.	2.2	115
24	Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion. Thyroid, 2006, 16, 709-710.	4.5	110
25	A phase II trial of pegylated interferon Î±-2b therapy for polycythemia vera and essential thrombocythemia. Cancer, 2006, 106, 2397-2405.	4.1	104
26	Activated Platelets Enhance IL-10 Secretion and Reduce TNF-Î± Secretion by Monocytes. Journal of Immunology, 2013, 191, 4059-4067.	0.8	104
27	Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal of Haematology, 2000, 110, 116-124.	2.5	100
28	Smoking and Increased White and Red Blood Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 965-977.	2.4	98
29	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology, 2013, 6, 49-58.	2.2	96
30	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research, 2013, 37, 1041-1045.	0.8	84
31	Idiopathic myelofibrosis: A clinical study of 80 patients. American Journal of Hematology, 1990, 34, 291-300.	4.1	79
32	Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology, 2009, 14, 331-334.	1.5	76
33	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	1.4	75
34	Hydroxycarbamide: a userâ€™s guide for chronic myeloproliferative disorders. Expert Review of Anticancer Therapy, 2011, 11, 403-414.	2.4	72
35	The rationale for B lymphocyte depletion in Gravesâ€™ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology, 2006, 154, 623-632.	3.7	71
36	Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology, 2019, 41, 5-19.	6.1	71

#	Article	IF	Citations
37	Ruxolitinib and interferon-Î±2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica, 2020, 105, 2262-2272.	3.5	67
38	A new era for IFN-Î± in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology, 2011, 4, 637-655.	2.2	66
39	A phase II study of vorinostat (<scp>MK</scp>â€0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2013, 162, 498-508.	2.5	65
40	The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	63
41	Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. American Journal of Hematology, 2003, 74, 26-31.	4.1	61
42	Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance. Leukemia Research, 2012, 36, 1387-1392.	0.8	60
43	Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-Î±. Blood, 2011, 118, 2170-2173.	1.4	59
44	Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. PLoS ONE, 2014, 9, e112786.	2.5	59
45	Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology, 2012, 40, 771-780.e19.	0.4	55
46	Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. European Journal of Haematology, 2011, 87, 54-60.	2.2	53
47	The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood, 2021, 137, 2152-2160.	1.4	51
48	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS ONE, 2017, 12, e0183620.	2.5	51
49	Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2012, 53, 123-129.	1.3	50
50	High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. European Journal of Internal Medicine, 2015, 26, 344-347.	2.2	49
51	World Health Organizationâ€defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlationsâ€"The Danish experience. American Journal of Hematology, 2013, 88, 1012-1016.	4.1	48
52	B-cell depletion with rituximab in the treatment of autoimmune diseases. Expert Opinion on Biological Therapy, 2007, 7, 1061-1078.	3.1	46
53	FLT3-Mediated p38â€"MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. Cancer Research, 2011, 71, 2901-2915.	0.9	46
54	Expansion of circulating CD56^{bright} natural killer cells in patients with JAK2â€positive chronic myeloproliferative neoplasms during treatment with interferonâ€Î±. European Journal of Haematology, 2015, 94, 227-234.	2.2	45

#	Article	IF	Citations
55	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-Î± via JAK1/STAT1 activation. Leukemia, 2019, 33, 995-1010.	7.2	43
56	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopeniaâ€¨and neutropenia. European Journal of Haematology, 2001, 66, 408-411.	2.2	41
57	Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Leukemia Research, 2009, 33, 11-18.	0.8	40
58	Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leukemia and Lymphoma, 2013, 54, 2269-2273.	1.3	40
59	Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology, 2014, 7, 203-216.	2.2	40
60	Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leukemia and Lymphoma, 2016, 57, 348-354.	1.3	40
61	Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2014, 38, 490-495.	0.8	38
62	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. PLoS ONE, 2016, 11, e0165336.	2.5	38
63	Safety and efficacy of combination therapy of interferonâ€Î±2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 2018, 7, 3571-3581.	2.8	38
64	B-cell depletion with rituximabâ€”a targeted therapy for Gravesâ€™ disease and autoimmune thyroiditis. Immunology Letters, 2003, 88, 85-86.	2.5	37
65	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia, 2022, 36, 1408-1411.	7.2	37
66	Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. American Journal of Hematology, 2002, 69, 185-191.	4.1	36
67	Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leukemia Research, 2015, 39, 1137-1145.	0.8	36
68	Smoking and philadelphiaâ€negative chronic myeloproliferative neoplasms. European Journal of Haematology, 2016, 97, 63-69.	2.2	36
69	Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. American Journal of Hematology, 2003, 74, 238-242.	4.1	35
70	Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?. Leukemia Research, 2006, 30, 1217-1225.	0.8	34
71	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. British Journal of Haematology, 2011, 155, 248-255.	2.5	34
72	Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms â€“ Impact Of Comorbidity . Clinical Epidemiology, 2019, Volume 11, 955-967.	3.0	34

#	Article	IF	Citations
73	Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives. Current Drug Targets, 2011, 12, 392-419.	2.1	34
74	Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases.. Apmis, 1991, 99, 171-178.	2.0	33
75	Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. American Journal of Hematology, 2013, 88, 843-847.	4.1	33
76	Second malignancies in hydroxyurea and interferonâ€treated Philadelphiaâ€negative myeloproliferative neoplasms. European Journal of Haematology, 2017, 98, 75-84.	2.2	33
77	Idiopathic myelofibrosis â€" an update with particular reference to clinical aspects and prognosis. International Journal of Clinical and Laboratory Research, 1993, 23, 124-138.	1.0	32
78	Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica, 2007, 92, 597-604.	3.5	31
79	Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study. Journal of Internal Medicine, 2016, 279, 566-575.	6.0	31
80	Smoking is associated with increased risk of myeloproliferative neoplasms: A general populationâ€based cohort study. Cancer Medicine, 2018, 7, 5796-5802.	2.8	31
81	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leukemia Research Reports, 2013, 2, 1-3.	0.4	30
82	Interferonâ€Î± induces marked alterations in circulating regulatory T cells, <scp>NK</scp> cell subsets, and dendritic cells in patients with <scp>JAK</scp>2V617Fâ€positive essential thrombocythemia and polycythemia vera. European Journal of Haematology, 2016, 97, 83-92.	2.2	30
83	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology, 2018, 7, e1433521.	4.6	30
84	INTERFERON IN MYELOFIBROSIS. Lancet, The, 1988, 331, 355.	13.7	29
85	Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms. JAMA Ophthalmology, 2017, 135, 835.	2.5	29
86	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 637420.	2.8	29
87	Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. American Journal of Hematology, 2002, 70, 92-99.	4.1	27
88	Prognostic factors in idiopathic myelofibrosis: A simple scoring system with prognostic significance. European Journal of Haematology, 1990, 44, 172-178.	2.2	27
89	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer Journal, 2019, 9, 8.	6.2	27
90	Smoking, blood cells and myeloproliferative neoplasms: metaâ€analysis and Mendelian randomization of 2Â·3 million people. British Journal of Haematology, 2020, 189, 323-334.	2.5	27

#	Article	IF	Citations
91	A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. European Journal of Haematology, 1991, 46, 285-289.	2.2	26
92	Idiopathic myelofibrosis: A review. European Journal of Haematology, 1990, 45, 65-72.	2.2	26
93	The plateletâ€“cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research, 2014, 38, 1230-1236.	0.8	26
94	Genomic profiling of a randomized trial of interferon-Î± vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	5.2	26
95	Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology, 2017, 10, 393-404.	2.2	25
96	Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 41, 27-35.	0.8	24
97	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2015, 126, 825-825.	1.4	24
98	Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients. Blood, 2016, 128, 475-475.	1.4	24
99	A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: Evidence of an autoimmune pathogenesis. American Journal of Hematology, 1987, 25, 225-229.	4.1	23
100	Evidence for an association between hairy cell leukemia and renal cell and colorectal carcinoma. Cancer, 1992, 70, 2087-2090.	4.1	23
101	Thrombopoietin-receptor agonists in haematological disorders: The Danish experience. Platelets, 2012, 23, 423-429.	2.3	23
102	A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research, 2014, 38, 263-266.	0.8	23
103	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology, 2009, 14, 11-15.	1.5	22
104	A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica, 2014, 99, e5-e7.	3.5	22
105	Circulating <scp>YKL</scp>â€40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. European Journal of Haematology, 2014, 93, 224-228.	2.2	21
106	Nonâ€invasive imaging of retinal blood flow in myeloproliferative neoplasms. Acta Ophthalmologica, 2017, 95, 146-152.	1.1	21
107	Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. European Journal of Haematology, 2019, 102, 235-240.	2.2	21
108	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets, 2019, 30, 206-212.	2.3	21

#	Article	IF	Citations
109	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine and Growth Factor Reviews, 2021, 60, 28-45.	7.2	21
110	Dataâ€driven analysis of JAK2 V617F kinetics during interferonâ€alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Medicine, 2020, 9, 2039-2051.	2.8	21
111	Serum Prolactin and Thyrotropin Responses to Thyrotropinâ€Releasing Hormone in Men with Alcoholic Cirrhosis. Acta Medica Scandinavica, 1981, 209, 37-40.	0.0	20
112	Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2011, 29, e564-e565.	1.6	20
113	<scp>A</scp>ssociation of the blood eosinophil count with hematological malignancies and mortality. American Journal of Hematology, 2015, 90, 225-229.	4.1	20
114	Circulating immune complexes in myelofibrosis. Scandinavian Journal of Haematology, 1985, 34, 177-180.	0.0	19
115	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica, 2010, 95, 2153-2156.	3.5	19
116	Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet Haematology,the, 2015, 2, e289-e296.	4.6	19
117	Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?. Leukemia and Lymphoma, 2016, 57, 1793-1799.	1.3	19
118	Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study. EClinicalMedicine, 2020, 21, 100280.	7.1	19
119	Serum hyaluronan is increased in malignant lymphoma. American Journal of Hematology, 1995, 50, 231-233.	4.1	18
120	Serum procollagen III peptide in chronic myeloproliferative disorders. Scandinavian Journal of Haematology, 1985, 35, 550-557.	0.0	18
121	Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. European Journal of Haematology, 2015, 94, 96-98.	2.2	18
122	Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clinical Epidemiology, 2019, Volume 11, 23-33.	3.0	18
123	A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden. PLoS ONE, 2012, 7, e33100.	2.5	18
124	Elevated plasma levels of TIMPâ€1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. European Journal of Haematology, 2003, 71, 377-384.	2.2	17
125	Recombinant interferonâ€alphaâ€2b treatment of hairyâ€cell leukaemia: Experience with a lowâ€dose schedule. European Journal of Haematology, 1988, 41, 438-444.	2.2	17
126	The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leukemia and Lymphoma, 2017, 58, 1914-1921.	1.3	17

#	Article	IF	Citations
127	Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. European Journal of Haematology, 2018, 100, 550-559.	2.2	17
128	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	3.7	17
129	New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e645.	2.7	17
130	Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 1991, 53, 35-43.	1.0	16
131	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology, 2008, 13, 71-76.	1.5	16
132	Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica, 2008, 93, 945-946.	3.5	16
133	The Copenhagen Primary Care Differential Count (CopDiff) database. Clinical Epidemiology, 2014, 6, 199.	3.0	16
134	Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leukemia and Lymphoma, 2016, 57, 125-128.	1.3	16
135	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. Scientific Reports, 2017, 7, 6774.	3.3	16
136	Cancer immune therapy for myeloid malignancies: present and future. Seminars in Immunopathology, 2019, 41, 97-109.	6.1	16
137	A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. Quality of Life Research, 2016, 25, 835-846.	3.1	15
138	Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leukemia and Lymphoma, 2018, 59, 973-977.	1.3	15
139	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology, 2018, 7, e1468957.	4.6	15
140	Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting. PLoS ONE, 2014, 9, e99388.	2.5	15
141	The impact of ruxolitinib treatment on inflammationâ€mediated comorbidities in myelofibrosis and related neoplasms. Clinical Case Reports (discontinued), 2015, 3, 499-503.	0.5	14
142	Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget, 2015, 6, 40588-40597.	1.8	14
143	Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art. Mediators of Inflammation, 2015, 2015, 1-3.	3.0	14
144	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology, 2016, 21, 387-391.	1.5	14

#	Article	IF	Citations
145	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. Blood, 2015, 126, 824-824.	1.4	14
146	Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden.. Blood, 2008, 112, 1750-1750.	1.4	14
147	Transition of Myelofibrosis to Polycythaemia Vera. Scandinavian Journal of Haematology, 1983, 30, 161-166.	0.0	13
148	The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. Apmis, 2011, 119, 498-504.	2.0	13
149	High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leukemia Research, 2011, 35, 1330-1334.	0.8	13
150	Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation. PLoS ONE, 2014, 9, e85567.	2.5	13
151	Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. Expert Review of Hematology, 2015, 8, 439-445.	2.2	13
152	Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancers, 2020, 12, 573.	3.7	13
153	A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. Cancer Genetics and Cytogenetics, 2007, 172, 107-112.	1.0	12
154	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 2014, 38, 816-821.	0.8	12
155	Effects of rituximab and dexamethasone on regulatory and proinflammatory Bâ€cell subsets in patients with primary immune thrombocytopenia. European Journal of Haematology, 2018, 100, 45-52.	2.2	12
156	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunology, Immunotherapy, 2020, 69, 315-324.	4.2	12
157	Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection. , 1999, 61, 135-138.		11
158	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. European Journal of Haematology, 2002, 69, 43-49.	2.2	11
159	Nonâ€Hodgkin malignant lymphomas and Hodgkin's disease in firstâ€degree relatives. Scandinavian Journal of Haematology, 1986, 36, 398-401.	0.0	11
160	Immunological recovery and dose evaluation in IFNâ€Î± treatment of hairy cell leukemia: Analysis of leukocyte differentiation antigens, NK and 2â€˜,5â€™â€oligoadenylate synthetase activity. European Journal of Haematology, 1989, 42, 50-59.	2.2	11
161	The Danish National Chronic Myeloid Neoplasia Registry. Clinical Epidemiology, 2016, Volume 8, 567-572.	3.0	11
162	Association of the blood eosinophil count with end-organ symptoms. Annals of Medicine and Surgery, 2019, 45, 11-18.	1.1	11

#	Article	IF	Citations
163	Bridging blood cancers and inflammation: The reduced Cancitis model. Journal of Theoretical Biology, 2019, 465, 90-108.	1.7	11
164	Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. Blood, 2020, 136, 33-33.	1.4	11
165	Spongy Lymphoid Myelofibrosis as a Predictor of Hairy Cell Leukaemia or a Variant of Hairy Cell Leukaemia without Hairy Cells?. Scandinavian Journal of Haematology, 1984, 32, 135-144.	0.0	10
166	Plateletâ€associated IgG and IgM in myelofibrosis. Scandinavian Journal of Haematology, 1984, 32, 488-492.	0.0	10
167	Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?. Gynecologic Oncology, 2015, 139, 312-318.	1.4	10
168	The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy. OncoImmunology, 2017, 6, e1358334.	4.6	10
169	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). Platelets, 2017, 28, 478-483.	2.3	10
170	Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis. Surgical Oncology, 2018, 27, 208-215.	1.6	10
171	Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?. Haematologica, 2019, 104, 2119-2125.	3.5	10
172	Ageâ€related prevalence and clinical significance of neutropenia â€•isolated or combined with other cytopenias: Real world data from 373â€‰820 primary care individuals. American Journal of Hematology, 2020, 95, 521-528.	4.1	10
173	Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration. EClinicalMedicine, 2020, 26, 100526.	7.1	10
174	High Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule(CEACAM) 6 In Primary Myelofibrosis. Blood, 2010, 116, 4116-4116.	1.4	10
175	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
176	On the pathogenesis of angiogenesis in idiopathic myelofibrosis. American Journal of Hematology, 1990, 33, 151-151.	4.1	9
177	Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasmaâ€soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. European Journal of Haematology, 2003, 71, 276-282.	2.2	9
178	Eosinophilia in routine blood samples as a biomarker for solid tumor development â€“ A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database. Acta OncolÃ³gica, 2014, 53, 1245-1250.	1.8	9
179	A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. British Journal of Haematology, 2017, 177, 800-805.	2.5	9
180	Pericardial haematopoiesis with tamponade in myelofibrosis. Scandinavian Journal of Haematology, 1985, 34, 270-273.	0.0	8

#	Article	IF	Citations
181	Increased iron stores prolong the <scp>QT</scp> interval â€“ a general population study including 20Â261 individuals and metaâ€analysis of thalassaemia major. British Journal of Haematology, 2016, 174, 776-785.	2.5	8
182	A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leukemia Research Reports, 2016, 6, 20-23.	0.4	8
183	A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology, 2017, Volume 9, 141-150.	3.0	8
184	Myeloproliferative Neoplasms in Danish Twins. Acta Haematologica, 2018, 139, 195-198.	1.4	8
185	The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. European Journal of Cancer Care, 2018, 27, e12865.	1.5	8
186	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental Hematology, 2019, 79, 26-34.	0.4	8
187	Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?. HemaSphere, 2020, 4, e407.	2.7	8
188	Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimerâ€™s disease: evidences and perspectives. Journal of Neuroinflammation, 2020, 17, 248.	7.2	8
189	Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. Redox Biology, 2021, 41, 101895.	9.0	8
190	Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?. Annals of Hematology, 2019, 98, 101-109.	1.8	7
191	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	5.2	7
192	Response to pegylated interferon in a COVIDâ€19â€“positive elderly woman with primary myelofibrosis treated with ruxolitinib. Clinical Case Reports (discontinued), 2021, 9, 2228-2235.	0.5	7
193	Global dynamics of healthy and cancer cells competing in the hematopoietic system. Mathematical Biosciences, 2020, 326, 108372.	1.9	7
194	Ropeginterferon Alfaâ€2b: Efficacy and Safety in Different Age Groups. HemaSphere, 2020, 4, e485.	2.7	7
195	Urinary Free Cortisol During Pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1984, 63, 253-256.	2.8	6
196	The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders. Current Drug Targets, 2007, 8, 247-256.	2.1	6
197	A novel immunohistochemical sequential multiâ€labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis. Histopathology, 2012, 60, 554-560.	2.9	6
198	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. Leukemia Research, 2012, 36, 485-487.	0.8	6

#	Article	IF	Citations
199	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
200	Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study. British Journal of Haematology, 2021, 193, 83-92.	2.5	6
201	Dataâ€driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. European Journal of Haematology, 2021, 107, 624-633.	2.2	6
202	Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Blood, 2019, 134, 2978-2978.	1.4	6
203	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS ONE, 2016, 11, e0161570.	2.5	6
204	Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation. EClinicalMedicine, 2022, 43, 101248.	7.1	6
205	Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system. Aging, 2021, 13, 25763-25777.	3.1	6
206	Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE, 2022, 17, e0270669.	2.5	6
207	Alcohol Intolerance in the Hypereosinophilic Syndrome. Alcoholism: Clinical and Experimental Research, 1988, 12, 147-148.	2.4	5
208	Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-Î±-2b treatment. Leukemia Research, 1989, 13, 451-456.	0.8	5
209	Demonstrated Benefit of Continuous Interferon-Alpha-2b Therapy in Hairy Cell Leukemia. A Two-Year Follow-Up. Leukemia and Lymphoma, 1991, 5, 23-31.	1.3	5
210	Serum laminin P1 in idiopathic myelofibrosis and related diseases. Leukemia Research, 1994, 18, 623-628.	0.8	5
211	Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage.. Apmis, 2007, 115, 778-783.	2.0	5
212	Redâ€Cell Sensitization in Myelofibrosis. Scandinavian Journal of Haematology, 1984, 32, 179-182.	0.0	5
213	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the preâ€diagnostic period. American Journal of Hematology, 2017, 92, E130-E132.	4.1	5
214	Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis. Leukemia and Lymphoma, 2019, 60, 2549-2557.	1.3	5
215	The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. European Journal of Haematology, 2020, 104, 46-54.	2.2	5
216	Increased oxidative stress with substantial dysregulation of genes related to oxidative stress and DNA repair after laparoscopic colon cancer surgery. Surgical Oncology, 2020, 35, 71-78.	1.6	5

#	Article	IF	Citations
217	Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study. EClinicalMedicine, 2020, 21, 100295.	7.1	5
218	Increased Expression of Proteasome-Related Genes In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4117-4117.	1.4	5
219	Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a. Blood, 2013, 122, 5241-5241.	1.4	5
220	Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. International Journal of Cardiology, 2022, 364, 112-118.	1.7	5
221	Myeloproliferative neoplasms in five multiple sclerosis patients. Leukemia Research Reports, 2013, 2, 61-63.	0.4	4
222	<scp>WHO</scp> classification 2008 of myeloproliferative neoplasms: a workshop learning effect â€“ the Danish experience. Apmis, 2015, 123, 787-792.	2.0	4
223	Molecular profiling as a novel tool to predict response to interferonâ€Î±2 in MPNs: The proof of concept in early myelofibrosis. Cancer, 2017, 123, 2600-2603.	4.1	4
224	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood, 2012, 120, 803-803.	1.4	4
225	Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 429-433.	1.2	4
226	A possible role for STI571 in the treatment of idiopathic myelofibrosis. American Journal of Hematology, 2001, 68, 63-64.	4.1	3
227	Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. Apmis, 2007, 115, 1267-1273.	2.0	3
228	Hairyâ€cell leukaemia simulating connective tissue disease. Scandinavian Journal of Haematology, 1984, 32, 457-460.	0.0	3
229	FURTHER EVIDENCE OF THE EFFICACY OF INTERFERON FOR Tâ€CELL HAIRY CELL LEUKAEMIA: To the Editor:. European Journal of Haematology, 1988, 40, 188-189.	2.2	3
230	Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. Blood, 2018, 132, 4326-4326.	1.4	3
231	Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.. Blood, 2004, 104, 4747-4747.	1.4	3
232	Glivec/STI571 Treatment Stimulates Megakaryopoiesis and Normalizes PDGF Receptor beta Kinase Expression in Thrombocytopenic Patients with Myeloid Metaplasia with Myelofibrosis.. Blood, 2005, 106, 2599-2599.	1.4	3
233	An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. Blood, 2012, 120, 2844-2844.	1.4	3
234	Urinary hydroxyproline excretion in the myelofibrosisâ€osteomyelosclerosis syndrome and related diseases. European Journal of Haematology, 1987, 39, 447-451.	2.2	2

#	Article	IF	Citations
235	Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]. Current Drug Targets, 2011, 12, 387-391.	2.1	2
236	Neo-antigen specific memory T-cell responses in healthy individuals. OncoImmunology, 2019, 8, e1599640.	4.6	2
237	Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm. EClinicalMedicine, 2020, 22, 100337.	7.1	2
238	Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer, 2021, 21, 691.	2.6	2
239	Response to pegylated interferon in a COVIDâ€19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus. Clinical Case Reports (discontinued), 2021, 9, e04218.	0.5	2
240	Doseâ€dependent mathematical modeling of interferonâ€Î±â€treatment for personalized treatment of myeloproliferative neoplasms. Computational and Systems Oncology, 2021, 1, .	1.5	2
241	Response: cancer risk in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3862-3863.	1.4	1
242	Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.. Blood, 2008, 112, 1744-1744.	1.4	1
243	FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.. Blood, 2009, 114, 963-963.	1.4	1
244	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study. Blood, 2015, 126, 5177-5177.	1.4	1
245	Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Blood, 2010, 116, 4119-4119.	1.4	1
246	Risks of Eosinophil-Related End-Organ Damage, Hematological Malignancies and Death Are Significantly Increased Even below Consensus Threshold Criteria for Blood Eosinophilia. Blood, 2013, 122, 2831-2831.	1.4	1
247	Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials. Blood, 2021, 138, 3660-3660.	1.4	1
248	Editorial [Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch)]. Current Drug Targets, 2007, 8, 203-203.	2.1	0
249	Quantitative PCR Assessment of JAK2 Mutational Status in Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders - The JAK2 V617F Mutation Is an Event in an Early Stem Cell and the Clonal Involvement of Different Haematopoietic Cells Varies between Individual Patients.. Blood, 2006, 108, 3602-3602.	1.4	0
250	Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.. Blood, 2007, 110, 4641-4641.	1.4	0
251	The Importance of a Bone Marrow Biopsy to Distinguish Primary Immune Thrombocytopenia From Indolent Haematological Malignancies. Blood, 2010, 116, 4676-4676.	1.4	0
252	Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis. Blood, 2010, 116, 4118-4118.	1.4	0

#	Article	IF	Citations
253	Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum From Essential Thrombocythemia Over Polycythemia Vera to Myelofibrosis. Blood, 2010, 116, 4115-4115.	1.4	0
254	The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,. Blood, 2011, 118, 3834-3834.	1.4	0
255	Polycythemia-Inducing Mutations In The Erythropoietin Receptor (EPOR): Mechanism and Function Elucidated By EGFRâ€“ EPOR Chimeras. Blood, 2013, 122, 2174-2174.	1.4	0
256	Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage â€“ a Population-Based Study. Blood, 2014, 124, 2791-2791.	1.4	0
257	DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes. Blood, 2014, 124, 4576-4576.	1.4	0
258	Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?. Blood, 2015, 126, 4444-4444.	1.4	0
259	A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis. Blood, 2015, 126, 4057-4057.	1.4	0
260	The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms. Blood, 2015, 126, 4097-4097.	1.4	0
261	Effects of Rituximab and Dexamethasone on Regulatory and Pro-Inflammatory B-Cell Subsets in Patients with Primary Immune Thrombocytopenia. Blood, 2016, 128, 1378-1378.	1.4	0
262	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. Blood, 2021, 138, 3627-3627.	1.4	0
263	The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients. Blood, 2021, 138, 3589-3589.	1.4	0
264	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	4.8	0